Taub R N, Lance E M
Immunology. 1968 Nov;15(5):633-42.
The effects of heterologous anti-lymphocyte serum (ALS) were studied in a syngeneic cell transfer system, in which lymph node cells from donor CBA mice were labelled with Cr and transferred intravenously into syngeneic recipients. Labelled cells treated with ALS were unable to migrate to lymph nodes or spleens of recipients, as did normal cells, but instead distributed themselves very similarly to cells which had been killed by exposure to heat. It is thus likely that cells treated with ALS are killed after transfer by the cytotoxic action of ALS mediated by the complement of the recipient. ALS administered directly to the recipients of labelled lymphocytes could also reduce their uptake into lymphoid tissue; however, the magnitude of this effect appeared to be critically dependent upon the timing of the antiserum dose with respect to the labelled cell dose. ALS given immediately prior to labelled cells showed the greatest effect, while treatment given either 24 hours before or after the labelled cells was much less effective. While with prior treatment the reduced effect could be due to a fall off in antibody titre during the interval between the dose of antiserum and cells, in the latter situation no drop in titre would have occurred. It thus seems that lymphocytes that have already established themselves in lymphoid tissue may be less susceptible to the action of ALS. ALS given chronically to lymphoid cell donors resulted in a population of cells which upon transfer to normal recipients were distributed differently from either normal or NRS-treated donor cells. These data support the hypothesis that the effects of ALS may be exerted preferentially on circulating lymphocytes, and that ALS may act to selectively reduce the representation of this cell type in lymphoid tissue.
在同基因细胞转移系统中研究了异种抗淋巴细胞血清（ALS）的作用，在该系统中，将来自供体CBA小鼠的淋巴结细胞用铬标记，然后静脉注射到同基因受体中。用ALS处理的标记细胞无法像正常细胞那样迁移到受体的淋巴结或脾脏，而是其分布与受热杀死的细胞非常相似。因此，经ALS处理的细胞在转移后很可能因受体补体介导的ALS的细胞毒性作用而被杀死。直接给标记淋巴细胞的受体注射ALS也可减少其被淋巴组织摄取；然而，这种作用的程度似乎严重依赖于抗血清剂量相对于标记细胞剂量的给药时间。在标记细胞之前立即给予ALS显示出最大的效果，而在标记细胞之前或之后24小时给予治疗则效果要小得多。对于预先治疗，效果降低可能是由于在抗血清剂量和细胞剂量之间的间隔期抗体滴度下降，而在后一种情况下不会出现滴度下降。因此，似乎已经在淋巴组织中定植的淋巴细胞可能对ALS的作用不太敏感。长期给淋巴细胞供体注射ALS会导致一群细胞，将其转移到正常受体后，其分布与正常或经正常兔血清（NRS）处理的供体细胞均不同。这些数据支持以下假设：ALS的作用可能优先作用于循环淋巴细胞，并且ALS可能起到选择性减少淋巴组织中这种细胞类型数量的作用。
